Myriad Genetics, Inc. (MYGN)

Myriad Genetics, Inc. (MYGN) is a healthcare company (diagnostics & research) based in the United States. The share price is $5.45, down 2.15% on the day, which values the company at $522.78M. Price as of 17 Nov 2026, 18:21 UTC, from Yahoo Finance.

Key facts

Share price
$5.45−2.15% today
Market value
$522.78M
Funk Score
40/100
Against its own history
Well below its usual priceusual price $18.63
200-week average
$13.7360% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Myriad Genetics, Inc. in more detail

MYGN trades at -8.1× next year's expected earnings, 0.7× sales. Measured against its own history, the price is 71% below what its usual multiples would imply ($18.63) — well below its usual price. It sits 60% below its 200-week average of $13.73.

Over the last five fiscal years Myriad Genetics, Inc. has compounded revenue 5.2% a year. Its Funk Score is 40 out of 100 (financial strength 2.9, profitability 2.6, growth 4.6, value 6.0, each out of 10).

Worth checking: Altman Z in the distress zone; Share count keeps rising.

Myriad Genetics, Inc. (MYGN): questions and answers

What is MYGN's PEG ratio?

Myriad Genetics, Inc.'s PEG ratio is 1.24 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Myriad Genetics, Inc.'s market cap?

Myriad Genetics, Inc. is valued at $522.78M at a share price of $5.45.

Is MYGN overvalued or undervalued?

Against its own history, MYGN is well below its usual price: the price is 71% below the $18.63 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is MYGN above its 200-week moving average?

No. MYGN is 60.3% below its 200-week average of $13.73. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Myriad Genetics, Inc. growing?

Over the last five fiscal years Myriad Genetics, Inc.'s revenue grew 5.2% a year; over ten years revenue grew 1.3% a year.

Does MYGN pay a dividend?

Myriad Genetics, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Myriad Genetics, Inc. (MYGN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MYGN

Underlying data: Yahoo Finance; company filings with the SEC.